Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

(2017) Chiara Crotti et al.   Drug Design Development and Therapy

SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis

(2016) M. Weinblatt et al.   ANNALS OF THE RHEUMATIC DISEASES

Lung involvement in inflammatory rheumatic diseases

(2016) Clive Kelly et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

The challenging interplay between rheumatoid arthritis, ageing and comorbidities

(2016) Marloes van Onna et al.   BMC MUSCULOSKELETAL DISORDERS

Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation

(2016) Adrian Achuthan et al.   JOURNAL OF CLINICAL INVESTIGATION

Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study

(2015) Nathalie Berghen et al.   CLINICAL RHEUMATOLOGY

Management of neutropenia in patients with rheumatoid arthritis

(2015) Estibaliz Lazaro et al.   JOINT BONE SPINE

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

(2015) Jasvinder A Singh et al.   LANCET

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

(2014) Maya H Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

(2014) D E A Greven et al.   ANNALS OF THE RHEUMATIC DISEASES

Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin

(2013) Marie Jaguin et al.   CELLULAR IMMUNOLOGY

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis

(2012) RR Minter et al.   BRITISH JOURNAL OF PHARMACOLOGY

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

(2012) J. Listing et al.   RHEUMATOLOGY

Pulmonary Alveolar Proteinosis

(2011) A. Khan et al.   Respiratory Care

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome

(2010) Y. Tsuchiya et al.   EUROPEAN RESPIRATORY JOURNAL

GM-CSF pathway correction in pulmonary alveolar proteinosis

(2010) Sabina A Antoniu   EXPERT OPINION ON BIOLOGICAL THERAPY

G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis

(2009) Ann L. Cornish et al.   Nature Reviews Rheumatology